Acquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension Velaris Therapeutics, the ninth
Leadership team brings proven company-building and drug development experience to Paragon following $10.9 billion acquisition of Apogee by AbbVie Velaris is the ninth company launched around Paragon-discovered assets
FORT LAUDERDALE, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (NASDAQ:TCRT) today announced that it has entered into definitive agreements with institutional investors in a registered direct
This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this modelLiver-weight findings are
ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver
FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (NASDAQ:TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the
Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership TeamSAN ANTONIO, May 4, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.)
The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse modelALN1003 also demonstrated reductions in liver weight and improvements in select
HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (NASDAQ:TCRT) (the "Company") today announced that it has entered into a definitive agreement with certain investors (the "SPA") for the purchase
NEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC ("PMGC Capital"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB), today issued a public statement urging Alaunos Therapeutics,
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC ("PMGC Capital," "we," "our," or "us"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB), today announced its planned filing of a
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patientshunTR® discovered
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patientsCompany to wind down
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics
TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indicationsTreatment was well tolerated with a
